Clinical Trial Finder

Inclusion Criteria:

For Cohort 1: Subjects with LN: 1. Clinical diagnosis of systemic lupus erythematosus (SLE) per 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria (Aringer 2019) 2. Active kidney disease with biopsy-proven active LN Class III or IV (coexistent class V permitted) (per 2018 International Society of Nephrology [ISN]/Renal Pathology Society [RPS] criteria); biopsy should be performed within 6 months before enrolling in the study. 3. ECOG performance ≤ 2. 4. Proteinuria (or urine protein creatinine ratio [UPCR]) > 1g / 24 hours.For Cohort 1: Subjects with SLE with Extrarenal Involvement. 1. Clinical diagnosis of systemic lupus erythematosus (SLE) per 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria (Aringer 2019). 2. Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≥ 8 with a clinical SLEDAI-2K score (SLEDAI-2K not including points for anti-dsDNA and/or low complement) ≥ 6 and/or ≥ 1 British Isles Lupus Assessment Group (BILAG)-2004 Category A. 3. Positive anti-nuclear antibody (ANA) test results and/or a positive anti-dsDNA and/or anti-Smith antibodies above the ULN. 4. Estimated creatinine clearance ≥ 60 mL/min. 5. Inadequate response in terms of active disease despite treatment with current standard of care for SLE including corticosteroids and at least 2 SLE therapy.For Cohort 2: Subjects with SSc. 1. Disease duration ≤ 6 years (from onset of first non-Raynaud manifestation) 2. Participants with diffuse cutaneous SSc with worsening skin disease, must meet both of the following criteria: mRSS ≥ 15 at screening AND one of the following within 6 months prior to screening: (i) mRSS increase of ≥ 3 units in the total mRSS, OR (ii) Involvement of 1 new body area, OR (iii) Increase in mRSS ≥ 2 units in 1 body area. 3. Participants with diffuse or limited cutaneous SSc and ILD must meet both of the following criteria: ILD, i.e. fibrosis on HRCT within 4 months of screening AND Progression of ILD by FVC or HRCT in previous 24 months. 4. FVC ≥ 45% predicted, DLCO ≥ 40% 5. Exclude PAH defined as RVSP ≥ 45 mmHg or right atrial or ventricular enlargement or dilatation, or renal crisis within 1 year of enrollment.For Cohort 3: Subjects with AAV. 1. Diagnosis of AAV defined as either GPA or MPA according to the 2012 Chapel Hill Consensus Conference. 2. Positive for PR3-ANCA or MPO-ANCA. 3. Relapsed or refractory AAV after at least 1 standard-of-care immunosuppressive regimen in addition to steroids. 4. Severe disease (i.e., presence of one or more major AAV sign or symptom per the BVAS or ≥ 3 minor items, or at least the 2 renal items of proteinuria and hematuria due to vasculitis) 5. Adequate renal function: CrCl ≥ 30 mL/min. 6. Proteinuria ≤ 8 g/24 hour.For Cohort 4: Subjects with Idiopathic Inflammatory Myopathies. 1. Meets the 2017 ACR/EULAR classification criteria (Lundberg 2017) for probable/definite IIM. 2. Muscle weakness defined as Manual Muscle Testing (MMT)-8 score < 142/150, and ≥ 2 of the following abnormal core set measures: (i) Patient global assessment VAS ≥ 2 cm (on 10-cm VAS), (ii) Physician global assessment VAS ≥ 2 cm (10-cm VAS), (iii) HAQ-DI > 0.25 , (iv) Extra-muscular global activity VAS ≥ 2 cm (10-cm VAS) 3. Active disease defined as ≥ 1 of the following signs in the past 4 months: a) Elevated serum CK or aldolase levels ≥ 3 times ULN; b) Active myositis by muscle biopsy, muscle MRI, or EMG; c) Active DM rash and CDASI >14; d) Active interstitial lung disease. 4. Positivity for ≥ 1 myositis-specific antibody or myositis-associated antibody at screening. 5. Inadequate response or intolerance/contraindication to glucocorticoids and to ≥ 2 immunosuppressants for 3 months/drug.For Cohort 4: Subjects with Stiff Person Syndrome. 1. Meets the 2009 criteria for diagnosis of stiff person syndrome (SPS) (Dalakas 2009): (a) Stiffness of the axial muscles, particularly the abdominal and thoraco-lumbar paraspinals, leading to hyperlordosis; (b) Superimposed painful spasms triggered by unexpected tactile or auditory stimuli; (c) Severe anxiety with task-specific phobias especially in anticipation of physically challenging tasks; (d) Electromyographic evidence of continuous motor unit activity of agonist and antagonist muscles; (e) Absence of other neurological findings that may suggest an alternative diagnosis; (f) Highly positive anti-GAD titer (> 10,000 IU/mL in serum by ELISA or detectable in CSF) 2. Inadequate response or intolerance or contraindication to ≥ 1 treatment including chronic IVIG or other biologic.

Exclusion Criteria:

For all Subjects: 1. Presence of severe liver disease, Child-Pugh class B or C. 2. Prior treatment with any gene therapy, genetically modified cell therapy, or adoptive T cell therapy. 3. Autoimmune disease requiring prednisone higher than 0.5 mg/kg/day (or corticosteroid equivalent). 4. Subjects unwilling to participate in an extended safety monitoring period (LTFU protocol) 5. History of a clinically significant infection (including sepsis, pneumonia, bacteremia, fungal, viral and opportunistic infections) within 4 weeks prior to first dose of study drug which in the opinion of the Investigator may compromise the safety of the subject in the study.

Arms

Experimental: ADI-001 Dose Escalation

ADI-001 is administered via infusion with ascending dose levels as a single dose to determine the maximum tolerated dose (MTD) or maximum assessed dose (MAD) of ADI-001.

Experimental: ADI-001 Dose Extension

After dose level has been declared safe, additional patients can be enrolled at the declared safe dose to further investigate the safety profile of ADI-001.

Experimental: ADI-001 Dose Expansion

Dose Expansion ADI-001 is administered via infusion at the MTD/MAD to confirm recommended phase 2 dose (Part 2).

Interventions

Drug: - ADI-001

Anti-CD20 CAR-T

Drug: - Fludarabine

Chemotherapy for Lymphodepletion

Drug: - Cyclophosphamide

Chemotherapy for Lymphodepletion